Therefore, the credibility of VEGFA, NPHS1, WT1, CTGF, SYNPO, and PODXL as biomarkers for diagnosing and predicting the progression of DN can be proved at the clinical level. This evidence concerns the gene CCN2 and liver dysplastic nodule.